BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 27040706)

  • 1. Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia.
    Tam CS; Seymour JF; Roberts AW
    Semin Oncol; 2016 Apr; 43(2):274-9. PubMed ID: 27040706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.
    Mason KD; Khaw SL; Rayeroux KC; Chew E; Lee EF; Fairlie WD; Grigg AP; Seymour JF; Szer J; Huang DC; Roberts AW
    Leukemia; 2009 Nov; 23(11):2034-41. PubMed ID: 19641525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.
    Roberts AW; Seymour JF; Brown JR; Wierda WG; Kipps TJ; Khaw SL; Carney DA; He SZ; Huang DC; Xiong H; Cui Y; Busman TA; McKeegan EM; Krivoshik AP; Enschede SH; Humerickhouse R
    J Clin Oncol; 2012 Feb; 30(5):488-96. PubMed ID: 22184378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition.
    Davids MS; Letai A; Brown JR
    Leuk Lymphoma; 2013 Aug; 54(8):1823-5. PubMed ID: 23614795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies.
    Roberts AW; Huang D
    Clin Pharmacol Ther; 2017 Jan; 101(1):89-98. PubMed ID: 27806433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reprogramming cell death: BCL2 family inhibition in hematological malignancies.
    Scarfò L; Ghia P
    Immunol Lett; 2013; 155(1-2):36-9. PubMed ID: 24095849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma.
    Ng SY; Davids MS
    Clin Adv Hematol Oncol; 2014 Apr; 12(4):224-9. PubMed ID: 25003352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The rosy future of BCL-2 inhibition in chronic lymphocytic leukemia: pursuit of a worthy target.
    Brown JR
    Leuk Lymphoma; 2015; 56(10):2755-6. PubMed ID: 25971908
    [No Abstract]   [Full Text] [Related]  

  • 9. BCL-2 as a therapeutic target in chronic lymphocytic leukemia.
    Daniel C; Mato AR
    Clin Adv Hematol Oncol; 2017 Mar; 15(3):210-218. PubMed ID: 28398276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.
    Moia R; Diop F; Favini C; Kodipad AA; Gaidano G
    Expert Rev Hematol; 2018 May; 11(5):391-402. PubMed ID: 29561706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies.
    Yalniz FF; Wierda WG
    Drugs; 2019 Aug; 79(12):1287-1304. PubMed ID: 31313099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting BCL2 for the treatment of lymphoid malignancies.
    Anderson MA; Huang D; Roberts A
    Semin Hematol; 2014 Jul; 51(3):219-27. PubMed ID: 25048785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABT-199 for chronic lymphocytic leukemia.
    Seymour J
    Clin Adv Hematol Oncol; 2014 Oct; 12(10):698-700. PubMed ID: 25658896
    [No Abstract]   [Full Text] [Related]  

  • 14. BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics.
    S Soderquist R; Eastman A
    Mol Cancer Ther; 2016 Sep; 15(9):2011-7. PubMed ID: 27535975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Noxa-like BH3 mimetics for apoptosis-based therapeutic strategy in chronic lymphocytic leukemia.
    Billard C
    Mol Cancer Res; 2012 Jun; 10(6):673-6. PubMed ID: 22466256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia.
    Billard C
    Leukemia; 2012 Sep; 26(9):2032-8. PubMed ID: 22453662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutics targeting Bcl-2 in hematological malignancies.
    Ruefli-Brasse A; Reed JC
    Biochem J; 2017 Oct; 474(21):3643-3657. PubMed ID: 29061914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Bcl-2 in CLL.
    Rogalinska M; Kilianska ZM
    Curr Med Chem; 2012; 19(30):5109-15. PubMed ID: 22856663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia.
    Zhang LN; Li JY; Xu W
    Cancer Gene Ther; 2013 Jan; 20(1):1-7. PubMed ID: 23175245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.
    Roberts AW; Stilgenbauer S; Seymour JF; Huang DCS
    Clin Cancer Res; 2017 Aug; 23(16):4527-4533. PubMed ID: 28100580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.